The piv­ot: Turn­stone Bi­o­log­ics opens a new chap­ter with a switch to clin­i­cal de­vel­op­ment and a new ven­ture round to pay for it

In biotech, most star­tups get about 5 years to get their pre­clin­i­cal act in or­der and jump in­to hu­man stud­ies be­fore the back­ers get restive and start look­ing for the ex­its. At the 2015-found­ed Turn­stone Bi­o­log­ics, they hit that line. But in­stead of los­ing its in­vestors’ in­ter­est, it’s been pick­ing up speed and back­ers.

Now, with a lead on­colyt­ic virus in an ear­ly-stage study and a sec­ond ther­a­py from the TIL side poised for an IND, the team un­der CEO Sam­my Farah has changed the sto­ry to clin­i­cal de­vel­op­ment. And they scored an $80 mil­lion Se­ries D from a broad syn­di­cate to get this new chap­ter un­der way in style.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER